Treatment of oral mucositis by administering an ionic complex of chitosan and a negatively charged polysaccharide selected from heparin, heparan sulfate and dextran sulfate
A composition having an ionic complex of chitosan and a negatively charged polysaccharide, selected from the group consisting of heparin, heparan sulfate and dextran sulfate, for use in the treatment of mucositis in a mammalian subject, to a method of preventing or treating mucositis in a mammalian subject, by applying topically a composition having an ionic complex of chitosan and a negatively charged polysaccharide, selected from the group consisting of heparin, heparan sulfate and dextran sulfate. The composition further relates to a pharmaceutical composition for topical administration of an ionic complex of chitosan and heparin.
1. A method of treating oral mucositis in a mammalian subject comprising the steps: applying topically a composition comprising an ionic complex of chitosan and a negatively charged polysaccharide, selected from the group consisting of heparin, heparan sulfate and dextran sulfate, to a site in need of treatment wherein the composition has a charge ratio of positive charges in the chitosan to negative charges in the negatively charged polysaccharide in a range of 10:3 to 10:6.
2. The method according to claim 1 , wherein the chitosan has a degree of deacetylation in a range of 50 to 99%.
3. The method according to claim 1 , wherein the chitosan has a degree of deacetylation in a range of 80 to 95%.
4. The method according to claim 1 , wherein the negatively charged polysaccharide is heparin.
5. The method according to claim 1 , wherein the composition has a charge ratio of positive charges in the chitosan to negative charges in the negatively charged polysaccharide in a range of 10:4 to 10:5.
6. The method according to claim 1 , wherein the total concentration of the chitosan and the negatively charged polysaccharide in the composition is in a range of 0.1 to 5%, based on a total weight of the composition.
7. The method according to claim 1 , wherein the total concentration of the chitosan and the negatively charged polysaccharide in the composition is in a range of 0.1 to 3% by weight, based on a total weight of the composition.
8. The method according to claim 1 , wherein the total concentration of the chitosan and the negatively charged polysaccharide in the composition is in a range of 0.5 to 5%, based on a total weight of the composition.
9. The method according to claim 1 , wherein the total concentration of the chitosan and the negatively charged polysaccharide in the composition is in a range of 1 to 3% by weight, based on a total weight of the composition.
10. The method according to claim 1 , wherein the composition further comprising an antimicrobial agent.
11. The method according to claim 10 , where the antimicrobial agent is methyl paraben and/or propyl paraben.
12. The method according to claim 1 , wherein the composition further comprising an antifoaming agent.
13. The method according to claim 1 , wherein the oral mucositis is caused by treatment of cancer, chemotherapy, radiotherapy and/or stem cell therapy.
14. The method according to claim 1 , wherein the composition is applied in a form of a mouthwash.
15. The method according to claim 1 , wherein applying topically includes body surfaces selected from the group consisting of mouth and throat.
16. The method according to claim 1 , wherein the composition further comprising buffer, surfactant, viscosity adjusting agent, flavoring agent, antimicrobial agent and antifoaming agent.
17. A method of treating oral mucositis in a mammalian subject comprising the steps: applying topically a composition comprising an antimicrobial agent, an antifoaming agent, an ionic complex of chitosan and a negatively charged polysaccharide of heparin, the chitosan has a degree of deacetylation in a range of 80 to 95%, the composition has a charge ratio of positive charges in the chitosan to negative charges in the heparin in a range of 10:4 to 10:5, the composition having a total concentration of the chitosan and the heparin in a range of 0.1 to 3% by weight, to a body surface in need of treatment, wherein the body surface is selected from the group consisting of mouth and throat.